Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

What we’ve learned from three years of fighting COVID-19

By Andrew Powaleny  |    March 20, 2023
Three years ago, amidst an unprecedented public health crisis, biopharmaceutical industry made a commitment to fight COVID-19. Leveraging decades of research and investments in emerging technologies...   Read More

WTAS: Inflation Reduction Act already impacting R&D decisions

By Nicole Longo  |    January 17, 2023
The Inflation Reduction Act’s (IRA’s) drug price setting provisions, as predicted, are already impacting biopharmaceutical research & development (R&D) decisions. Whether you are looking at estimates...   Read More

Sparking conversations — and careers — at the 2nd annual Pathways to Success Summit

By Dr. Steven Thomas  |    December 8, 2022
On September 28-29, 2022, PhRMA hosted the second annual Pathways to Success: Virtual Graduate Summit and Career Expo. This event provided a unique opportunity for students and faculty from diverse...   Read More

Stories from the lab: Researchers discuss innovative treatments for cancers of the blood

By Matthew Norawong  |    December 1, 2022
The biopharmaceutical industry is one of the most research-intensive of all sectors in the U.S. economy and supports a broad range of STEM jobs through R&D and manufacturing. At the backbone of the...   Read More

Congratulations to our 2022 Working for Cures Employee Champions

By Stephen J. Ubl  |    November 10, 2022
The Working for Cures Employee Champion Awards celebrate the real people in our industry who go above and beyond to advance science and support the work our industry does for patients.   Read More

Protecting against influenza: A conversation with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus

By Michael Ybarra  |    October 13, 2022
Our industry is at the forefront of fighting the annual influenza virus. I recently had the chance to connect with David Ross, Vice President, Commercial Operations, North America, CSL Seqirus about...   Read More

An open letter to Congress: Stand with patients and future cures

By Stephen J. Ubl  |    August 4, 2022
I recently joined PhRMA board members in penning the letter below to Congress, urging them to abandon their latest drug pricing proposal. You can read the letter here or below:   Read More

PhRMA member companies’ R&D investments reach record high of $102.3 billion in 2021

By Tim McClung  |    July 18, 2022
PhRMA member companies’ continued investment in research and development (R&D) has led to new medicines transforming human health. Innovative biopharmaceutical approaches to treating patients for a...   Read More

Biopharmaceutical researchers to discuss the value of R&D with Congress

By Stephen J. Ubl  |    June 9, 2022
Today, researchers from PhRMA member companies will meet virtually with members of Congress and Capitol Hill staff to discuss the importance of biopharmaceutical innovation in bringing new treatments...   Read More

A conversation with Barry Greene, CEO of Sage Therapeutics

By Stephen J. Ubl  |    May 4, 2022
Our industry continues working to build a more resilient, affordable and equitable health care system. As part of Mental Health Awareness Month, I recently had the opportunity to connect with PhRMA...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates